文献速递精神分裂症与精神病性障碍

近期是否接受过治疗对精神分裂症急性期抗精神病药疗效的影响:个体参与者数据荟萃分析

Antipsychotic Acute-Phase Treatment in Individuals With and Without Recent Treatment: An Individual Participant Data Meta-Analysis.
PubMed 文献 · JAMA Psychiatry · 2025-01-01

该个体参与者数据荟萃分析纳入12项安慰剂对照的急性期抗精神病药随机临床试验,比较近期未治疗(≥4周未用抗精神病药)与近期治疗患者中抗精神病药(对比安慰剂)的疗效差异。结果显示两组间疗效差异无统计学意义(DMD 0.8 PANSS分,95%CI -3.6至5.2),但近期未治疗组在抗精神病药和安慰剂下均预后更好。

要点

  • 近期未治疗与近期治疗患者中,抗精神病药对比安慰剂的急性期疗效差异无统计学意义。
  • 近期未治疗组在抗精神病药和安慰剂下均比近期治疗组预后更好。
  • 临床决策不应仅基于近期是否用药来预期抗精神病药急性期疗效差异。

核心结论

  • 近期未治疗与近期治疗患者中,抗精神病药(对比安慰剂)急性期治疗与结局的关联可能相似。
  • 近期未治疗患者无论接受抗精神病药还是安慰剂,结局均优于近期治疗患者。

研究设计与样本

  • 个体参与者数据荟萃分析,检索Yale Open Data Access项目数据库至2024年4月16日。
  • 纳入12项安慰剂对照的急性期抗精神病药随机临床试验,对象为18岁及以上精神分裂症或分裂情感性障碍患者。
  • 近期未治疗组692例(抗精神病药502例,安慰剂190例),近期治疗组2089例(抗精神病药1513例,安慰剂576例)。
  • 总体中位年龄38岁(IQR 30-48),女性998例(35.9%)。

主要发现

  • 近期未治疗与近期治疗组间抗精神病药对比安慰剂的疗效差异无统计学意义(DMD 0.8 PANSS分,95%CI -3.6至5.2)。
  • 近期未治疗组在抗精神病药和安慰剂下均比近期治疗组结局更好。

关键数值与推荐

  • 近期未治疗定义为随机治疗开始前≥4周未接受抗精神病药治疗。
  • 主要结局为6周后PANSS总分。

临床怎么用

  • 对于精神分裂症或分裂情感性障碍急性期患者,不应仅凭近期是否用药来预期抗精神病药与安慰剂的疗效差异。
  • 近期未治疗患者整体预后更好,但仍需个体化评估治疗方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: It has been hypothesized that the association between acute-phase treatment with antipsychotic (vs placebo) and outcomes might be larger in individuals who were not recently treated compared to recently treated individuals. However, evidence is still lacking. OBJECTIVE: To compare the association between antipsychotic (vs placebo) acute-phase treatment and outcomes in individuals who were not recently treated to recently treated individuals. DATA SOURCES: The Yale University Open Data Access Project's database was searched from inception to April 16, 2024 (PROSPERO CRD42021224350). STUDY SELECTION: We included placebo-controlled antipsychotic acute-phase randomized clinical trials with participants with schizophrenia or schizoaffective disorder aged 18 years and older. Participants were divided into 2 groups: recently treated (treated with an antipsychotic before the start of randomized treatment) and not recently treated (not treated for ≥4 weeks before the start of randomized treatment). DATA EXTRACTION AND SYNTHESIS: Multiple linear regression models were implemented to estimate difference in mean difference (DMD), defined as mean difference (antipsychotic vs placebo) in not recently treated minus mean difference in recently treated, and 95% confidence intervals in each study. DMD and 95% confidence intervals were synthesized across studies using a random effects meta-analysis model. MAIN OUTCOMES AND MEASURES: The primary outcome was overall symptoms (Positive and Negative Syndrome Scale [PANSS] score after 6 weeks). RESULTS: A total of 470 trials were identified, of which 12 were eligible for the analysis. A total of 692 individuals were included in the not recently treated group and randomized to antipsychotic (n = 502) or placebo (n = 190), and 2089 individuals were included in the recently treated group and randomized to antipsychotic (n = 1513) or placebo (n = 576). Overall median (IQR) age of included individuals was 38 (30-48) years, and 998 individuals (35.9%) were female. No evidence of difference in the antipsychotic vs placebo outcomes was detected across the not recently treated and recently treated individuals (DMD, 0.8 PANSS points; 95% CI, -3.6 to 5.2). Not recently treated individuals had better outcomes with both the antipsychotic and placebo compared to recently treated individuals. CONCLUSIONS AND RELEVANCE: In this individual participant data meta-analysis, the association between antipsychotic (vs placebo) acute-phase treatment and outcomes may be similar in individuals with and without recent treatment. Individuals who were not recently treated had better outcomes with both the antipsychotic and placebo compared with recently treated individuals.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Brandt L, Efthimiou O, Siafis S, et al. Antipsychotic Acute-Phase Treatment in Individuals With and Without Recent Treatment: An Individual Participant Data Meta-Analysis. JAMA Psychiatry. 2025. PMID: 40332874. doi:10.1001/jamapsychiatry.2025.0587

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。